Hirudin in acute myocardial infarction: Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial

Circulation

Volumn 94, Issue 5, 1996, Pages 911-921

  Antman, Elliott M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

heparin; myocardial infarction; thrombolysis

Indexed keywords

PLASMINOGEN ACTIVATOR; STREPTOKINASE; THROMBIN INHIBITOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CARDIOGENIC SHOCK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY BLOOD VESSEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME;

EID: 0029788104     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.5.911     Document Type: Article

References (60)

1. The TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I Findings. N Engl J Med. 1985;312:932-936.
2. The GUSTO Angiographic Investigators. The comparative effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615-1622.
3. Cannon CP, McCabe CH, Diver DJ, Herson S, Greene RM, Shah PK, Sequeira RF, Leya F, Kirshenbaum JM, Magorien RD, Palmeri ST, Davis V, Gibson CM, Poole WK, Braunwald E, and the TIMI 4 Investigators. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol. 1994;24:1602-1610.
4. Ohman EM, Califf RM, Topol EJ, Candela R, Abbottsmith C, Ellis S, Sigmon KM, Kereiakes D, George B, Stack R, and the TAMI Study Group. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation. 1990;82:781-791.
5. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.
6. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J. 1994;308:81-106.
7. Roux S, Christeller S, Ludin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. J Am Coll Cardiol. 1992;19:671-677.
8. Weitz JI, Califf RM, Ginsberg JS, Hirsh J, Theroux P. New antithrombotics. Chest. 1995;108:471S-485S.
9. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385-391.
10. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1995;108:258S-275S.
11. Eisenberg PR. Role of new anticoagulants as adjunctive therapy during thrombolysis. Am J Cardiol. 1991;67:19A-24A.
12. Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res. 1994;74:1-23.
13. Cannon CP, Braunwald E. Hirudin: initial results in acute myocardial infarction, unstable angina, and angioplasty. J Am Coll Cardiol. 1995;25:30S-37S.
14. Rydel TJ, Ravichandran KG, Tulinsky A, Bode W, Huber R, Roitsch C, Fenton JW. The structure of a complex of recombinant hirudin and human alpha-thrombin. Science. 1990;249:277-280.
15. Dodt J, Muller H-P, Seemuller U, Chang J-Y. The complete amino acid sequence of hirudin, a thrombin specific inhibitor. FEBS Lett. 1984;165:180-184.
16. Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing reocclusion. Circulation. 1991;83:1048-1056.
17. Rigel DF, Olson RW, Lappe RW. Comparison of hirudin and heparin as adjuncts to streptokinase thrombolysis in a canine model of coronary thrombolysis. Circulation. 1993;72:1091-1102.
18. Cannon CP, McCabe CH, Henry TD, Schweiger M, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland JM, Anderson JL, Sharaf BL, Edwards SJ, Rogers WJ, Williams DO, Braunwald E, for the TIMI 5 Investigators. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 Trial. J Am Coll Cardiol. 1994;23:993-1003.
19. Lee LV, for the TIMI 6 Investigators. Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial. Am J Cardiol. 1995;75:7-13.
20. Antman EM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation. 1994;90:1624-1630.
21. Hirsh J. Heparin. N Engl J Med. 1991;324:1565-1574.
22. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel B, Willerson J, Williams DO, Zaret BL, Braunwald E. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase 1: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation. 1987;76:142-154.
23. Kaplan EL, Meier P. Nonparametric estimation form incomplete observations. J Am Star Assoc. 1958;53:457-481.
24. Hillis LD, Forman S, Braunwald E, and the Thrombolysis in Myocardial Infarction (TIMI) Phase II Co-Investigators. Risk stratification before thrombolytic therapy in patients with acute myocardial infarction. J Am Coll Cardiol. 1990;16:313-315.
25. Cairns J, Lewis HD Jr, Meade TW, Sutton GC, Theroux P. Antithrombotic agents in coronary artery disease. Circulation. 1995;95:380S-400S.
26. Rapaport SI, Rao VM. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb. 1992;12:1111-1120.
27. Weitz JI. Activation of blood coagulation by plaque rupture: mechanisms and prevention. Am J Cardiol. 1995;75:18B-22B.
28. Lee CD, Mann KG. Activation/inactivation of human factor V by plasmin. Blood. 1989;73:185-190.
29. Eisenberg PR, Sobel BS, Jaffe AS. Activation of prothrombin accompanying thrombolysis with recombinant tissue type plasminogen activator. J Am Coll Cardiol. 1992;19:1065-1069.
30. Fitzgerald DJ, Catella F, Roy L, Fitzgerald GA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation. 1988;77:142-150.
31. 2 modulate the response to tissue-type plasminogen activator in vivo. Circ Res. 1989;65:83-94.
32. Schini VB, Hendrickson H, Heublein DM, Burnett JC Jr, Vanhoutte PM. Thrombin enhances the release of endothelin from cultured porcine aortic endothelial cells. Eur J Pharmacol. 1989;165:333-334.
33. The SCATI Group. Randomised controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. Lancet. 1989;1:182-186.
34. The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet. 1990;336:71-75.
35. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet. 1990;336:65-71.
36. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
37. MacMahon S, Collins R, Knight C, Yusuf S, Peto R. Reduction in major morbidity and mortality by heparin in acute myocardial infarction. Circulation. 1988;78(suppl II):II-98. Abstract.
38. Ridker PM, Hebert PR, Fuster V, Hennekens CH. Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction? Lancet. 1993;341:1574-1577.
39. White HD, Yusuf S. Issues regarding the use of heparin following streptokinase therapy. J Thrombosis Thrombolysis. 1995;2:5-10.
40. Rogers WJ, Bowlby LJ, Chandra NC, French WJ, Gore JM, Lambrew CT, Rubison RM, Tiefenbrunn AJ, Weaver WD. Treatment of myocardial infarction in the United States (1990 to 1993): observations from the National Registry of Myocardial Infarction. Circulation. 1994;90:2103-2114.
41. Cannon CP, Henry TD, Schweiger MJ, Haugland JM, McKendall GR, Shah PK. Gleason R, McCabe CH, Antman EM, Braunwald E, for the TIMI 9 Registry Investigators and Coordinators. Current management of ST elevation myocardial infarction and outcome of thrombolytic ineligible patients: results of the multicenter TIMI 9 Registry. J Am Coll Cardiol. 1995;(special issue):231A-232A.
42. Galvani M, Abendschein DR, Ferrini D, Ottani F, Rusticali F, Eisenberg PR. Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase. J Am Coll Cardiol. 1994;24:1445-1452.
43. Heras M, Chesebro JH, Webster MWI, Mruk JS, Grill DE, Penny WJ, Bowie EJW, Badimon L, Fuster V. Hirudin, heparin and placebo during deep arterial injury in the pig: the in vivo role of thrombin in platelet-mediated thrombosis. Circulation. 1990;82:1476-1484.
44. Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs: heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation. 1989;79:657-665.
45. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. A randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 1994;90:1631-1637.
46. Neuhaus KL, von Essen R, Tebbe U, Jessel A, Heinrichs H, Mäurer W, During W, Harmjanz D, Kötter V, Kalhammer E, Simon E, Horacek T. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study: a study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALK). Circulation. 1994;90:1638-1642.
47. Topol EJ, George BS, Kereiakes DJ, Stump DC, Candela RJ, Abbottsmith CW, Aronson L, Pickel A, Boswick JM, Lee KL, Ellis SG, Califf RM, and the TAMI Study Group. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation. 1989;79:281-286.
48. Mruk JS, Zoldhelyi P, Webster MWI, Heras M, Grill DE, Holmes DR Jr, Fuster V, Chesebro JH. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin. Circulation. 1996;93:792-799.
49. Lee KL, Woodlief LH, Topol EJ, Weaver D, Betriu A, Col J, Simoons M, Aylward P, Van de Werf F, Califf RM, for the GUSTO-1 Investigators. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41 021 patients. Circulation. 1995;91:1659-1668.
50. American Heart Association. Heart and Stroke Facts: 1995 Statistical Supplement. Dallas, Tex: American Heart Association; 1995:1-23.
51. Detsky AS, Sackett DL. When was a 'negative' clinical trial big enough: how many patients you needed depends on what you found. Arch Intern Med. 1985;145:709-712.
52. Zoldhelyi P, Janssens S, Lefevre G, Collen D, Van de Werf F, for the GUSTO-2A Investigators. Effects of heparin and hirudin(CGP 39393) on thrombin generation during thrombolysis for acute myocardial infarction. Circulation. 1995;92(suppl I):I-740. Abstract.
53. Rao AK, Sun L, Chesebro JH, Fuster V, Harrington RA, Schwartz D, Gallo P, Matos D, Topol EJ. Distinct effects of recombinant desulfatohirudin CGP39,393 and heparin on plasma levels of fibrino-peptide A and prothrombin fragment F1.2 in unstable angina: a multicenter trial. Thromb Haemost. 1995;73:1306. Abstract.
54. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M. Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330-1335.
55. Abendschein DR, Meng YY, Torr-Brown S, Sobel BE. Maintenance of coronary patency after fibrinolysis with tissue factor pathway inhibitor. Circulation. 1995;92:944-949.
56. Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide: comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Circulation. 1992;85:805-815.
57. Yasuda T, Gold HK, Leinbach RC, Saito T, Guerrero L, Jang I-K, Holt R, Fallon JT, Collen D. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody. J Am Coll Cardiol. 1990;16:1728-1735.
58. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995;332:1553-1559.
59. Frishman WH, Burns B, Atac B, Alturk N, Altajar B, Lerrick K. Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Am Heart J. 1995;130:877-892.
60. Nicolini FA, Lee P, Rios G, Kotte-Marchant K, Topol EJ. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. Circulation. 1994;89:1802-1809.